Tatsiana V. Mokhort
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Tatsiana V. Mokhort has a total of 86 co-authors. Here are the top co-authors by number of shared publications:
- Volha Vasilkova
Gomel State Medical University
8 shared publications - Ivan Yu. Pchelin
Saint Petersburg State University
7 shared publications - Natalia D. Kolomiets
Belarusian State Medical University, Minsk, Republic of Belarus
6 shared publications - Ekaterina V. Fedorenko
Scienti c and Practical Centre of Hygiene
5 shared publications - Sergey Petrenko
Department of Anthropoecology and Epidemiology, International Sakharov Environmental University, Minsk, Belarus
5 shared publications - Alena G. Mokhort
Belarusian State Medical University, 220116, Minsk, Republic of Belarus
4 shared publications
Latest Publications
- Open Access
- 3 November 2026
- Published by MDPI AG in Cardiogenetics
- Vol. 16 (4) , 26
Beyond Traditional Risk Factors: The Role of the CYP11B2 C(-344)T Polymorphism in Atherosclerosis and Cardiorenal Syndrome Phenotypes in Diabetes Mellitus
Background: This study aimed to evaluate the association of the CYP11B2 C(-344)T polymorphism with cardiorenal phenotypes and atherosclerosis in patients with DM. Methods: A total of 269 patients with DM (180 with type 2 and 89 with type 1 diabetes) and 50 age-matched controls without DM were included in this study. Clinical, laboratory, echocardiographic, and vascular parameters were assessed, and CYP11B2 genotyping was performed by allele-specific PCR. Results: The T allele and TT genotype were significantly more frequent in patients with DM than in controls (64% and 47% vs. 48% and 26%, respectively) and were associated with adverse cardiorenal phenotypes. TT carriers also showed higher levels of homocysteine and fibroblast growth factor-23, as well as worse renal and vascular parameters. In multivariable analysis, the TT genotype was independently associated with higher odds of chronic kidney disease (OR 12.21, 95% CI 3.76–39.61), heart failure (OR 3.80, 95% CI 1.67–8.66), left ventricular hypertrophy (OR 2.17, 95% CI 1.02–4.59), and atherosclerosis (OR 2.33, 95% CI 1.02–5.32). Conclusions: The CYP11B2 C(-344)T polymorphism, particularly the TT genotype, was associated with increased risk of diabetic cardiorenal and atherosclerotic complications. These findings suggest that aldosterone synthase gene variation may contribute to diabetic cardiorenal and vascular complications and may be useful for future risk-stratification research.
- 3 November 2026
- Published by MDPI AG in Cardiogenetics
- Vol. 16 (4) , 26
Open AccessBeyond Traditional Risk Factors: The Role of the CYP11B2 C(-344)T Polymorphism in Atherosclerosis and Cardiorenal Syndrome Phenotypes in Diabetes Mellitus
Background: This study aimed to evaluate the association of the CYP11B2 C(-344)T polymorphism with cardiorenal phenotypes and atherosclerosis in patients with DM. Methods: A total of 269 patients with DM (180 with type 2 and 89 with type 1 diabetes) and 50 age-matched controls without DM were included in this study. Clinical, laboratory, echocardiographic, and vascular parameters were assessed, and CYP11B2 genotyping was performed by allele-specific PCR. Results: The T allele and TT genotype were significantly more frequent in patients with DM than in controls (64% and 47% vs. 48% and 26%, respectively) and were associated with adverse cardiorenal phenotypes. TT carriers also showed higher levels of homocysteine and fibroblast growth factor-23, as well as worse renal and vascular parameters. In multivariable analysis, the TT genotype was independently associated with higher odds of chronic kidney disease (OR 12.21, 95% CI 3.76–39.61), heart failure (OR 3.80, 95% CI 1.67–8.66), left ventricular hypertrophy (OR 2.17, 95% CI 1.02–4.59), and atherosclerosis (OR 2.33, 95% CI 1.02–5.32). Conclusions: The CYP11B2 C(-344)T polymorphism, particularly the TT genotype, was associated with increased risk of diabetic cardiorenal and atherosclerotic complications. These findings suggest that aldosterone synthase gene variation may contribute to diabetic cardiorenal and vascular complications and may be useful for future risk-stratification research.
- Open Access
- 30 March 2024
- Published by Gomel State Medical University in Health and Ecology Issues
- Vol. 21 (1) , 49-58
Features of structural and geometric cardiac remodeling in patients with diabetes mellitus depending on chronic kidney disease stages
Objective. To study the features of structural and geometric cardiac remodeling in patients with diabetes mellitus (DM) depending on the stage of chronic kidney disease (CKD). Materials and methods. We examined 499 patients (127 men and 322 women) with type 1 DM (133 people) and type 2 DM (316 people) aged 62 [52;69] years. The comparison group consisted of 65 randomly selected volunteering individuals (54 women and 11 men) without disorders of carbohydrate metabolism and kidney damage aged 59 [46;66] years. The laboratory examination of the patients included the measurement of serum creatinine, eGFR according to the CKD-EPI equation. An echocardiographic investigation was performed to study structural and geometric heart parameters. Left ventricular hypertrophy (LVH) was diagnosed when the left ventricular myocardial mass index (LVMI) exceeded 115 g/m2 in men and 95 g/m2 in women. Results. LVH was detected in 57.7 % of patients with DM, while in the comparison group – in 35.4 %. The frequency of LVH increased with a decrease in eGFR and was diagnosed in 100 % of cases with CKD 5. In patients with DM, the left ventricular concentric remodeling significantly predominated (29.2%). Multiple linear regression analysis demonstrated the influence of age (ß=0.30, p=0.01) and serum creatinine (ß = 0.15, p < 0.0001) on the LVMI, independent of other factors, which confirms their independent pathogenetic significance. Conclusion. Thus, patients with DM regardless of the CKD stage have structural and functional changes in the LV myocardium. Regardless of the nitrogen-excretion function of the kidneys, the predominant pattern of LV remodeling is concentric. The study of the features of structural and functional restructuring of the left heart in patients with diabetes should be taken into account in determining the cardiovascular prognosis.
- 30 March 2024
- Published by Gomel State Medical University in Health and Ecology Issues
- Vol. 21 (1) , 49-58
Open AccessFeatures of structural and geometric cardiac remodeling in patients with diabetes mellitus depending on chronic kidney disease stages
Objective. To study the features of structural and geometric cardiac remodeling in patients with diabetes mellitus (DM) depending on the stage of chronic kidney disease (CKD). Materials and methods. We examined 499 patients (127 men and 322 women) with type 1 DM (133 people) and type 2 DM (316 people) aged 62 [52;69] years. The comparison group consisted of 65 randomly selected volunteering individuals (54 women and 11 men) without disorders of carbohydrate metabolism and kidney damage aged 59 [46;66] years. The laboratory examination of the patients included the measurement of serum creatinine, eGFR according to the CKD-EPI equation. An echocardiographic investigation was performed to study structural and geometric heart parameters. Left ventricular hypertrophy (LVH) was diagnosed when the left ventricular myocardial mass index (LVMI) exceeded 115 g/m2 in men and 95 g/m2 in women. Results. LVH was detected in 57.7 % of patients with DM, while in the comparison group – in 35.4 %. The frequency of LVH increased with a decrease in eGFR and was diagnosed in 100 % of cases with CKD 5. In patients with DM, the left ventricular concentric remodeling significantly predominated (29.2%). Multiple linear regression analysis demonstrated the influence of age (ß=0.30, p=0.01) and serum creatinine (ß = 0.15, p < 0.0001) on the LVMI, independent of other factors, which confirms their independent pathogenetic significance. Conclusion. Thus, patients with DM regardless of the CKD stage have structural and functional changes in the LV myocardium. Regardless of the nitrogen-excretion function of the kidneys, the predominant pattern of LV remodeling is concentric. The study of the features of structural and functional restructuring of the left heart in patients with diabetes should be taken into account in determining the cardiovascular prognosis.
- Open Access
- 29 January 2024
- Published by Maad Rayan Publishing Company in Journal of Renal Injury Prevention
The role of inflammatory markers and growth factors in progression of chronic kidney disease in patients with diabetes mellitus
Introduction: A Diabetes mellitus (DM) and chronic kidney disease (CKD) are two chronic non-communicable diseases that have exceeded epidemic thresholds in all countries of the world. The problem of early diagnosis, prevention and treatment of CKD continues to be relevant for modern medicine, and assessment of the severity of CKD and associated cardiovascular complications is of great practical importance for primary and secondary prevention. Objectives: The aim of the study was to assess the role of proinflammatory cytokines, chemokines and growth factors in progression of CKD in patients with DM. Patients and Methods: We screened 155 type 2 DM patients aged 65.00 (55.00-71.00) years. Control group included 21 healthy people with the same age. Renal function was assessed based on the levels of serum creatinine, cystatin C, estimated glomerular filtration rate (eGFR), which was calculated according to the CKD-EPI (chronic kidney disease epidemiology collaboration) equation, and albuminuria, which was assessed as albumin/creatinine ratio (A/C). The analysis of serum and urine biomarkers was carried out by enzyme immunoassay using commercial test systems. Results: Patients with DM had significantly higher levels of proinflammatory cytokines in comparison with the control group. The levels of interleukin-6 (IL-6), high-sensitivity C-reactive protein (hs-CRP), vascular endothelial growth factor A (VEGF-A), fibroblast growth factor-23 (FGF-23), regulated upon activation, normal T cell expressed and presumably secreted (RANTES), MIG, CRP, kidney injury molecule-1 (KIM-1) and homocysteine gradually increased with decreasing GFR. According to the results of univariate linear regression analysis, there were significant relationships between the levels of VEGF-A, FGF-23, RANTES, tumor necrosis factor alpha (TNF-alpha), MIG, CRP, hs-CRP, IL-6 and renal function. By multiple linear regression analysis adjusted for confounding factors, serum creatinine was significantly correlated with FGF-23 (β=0.40, P<0.001) and Il-6 (β=0.29, P<0.001). Conclusion: Our study demonstrated the important role of growth factors and proinflammatory cytokines in the development and progression of CKD in DM. However, despite these data, the pathogenesis of diabetic changes in the kidneys remains not fully understood and, in order to clarify the possibility of pathogenetic influences on the progression of diabetic nephropathy, it is necessary to study various aspects of its development, including genetic factors.
- 29 January 2024
- Published by Maad Rayan Publishing Company in Journal of Renal Injury Prevention
Open AccessThe role of inflammatory markers and growth factors in progression of chronic kidney disease in patients with diabetes mellitus
Introduction: A Diabetes mellitus (DM) and chronic kidney disease (CKD) are two chronic non-communicable diseases that have exceeded epidemic thresholds in all countries of the world. The problem of early diagnosis, prevention and treatment of CKD continues to be relevant for modern medicine, and assessment of the severity of CKD and associated cardiovascular complications is of great practical importance for primary and secondary prevention. Objectives: The aim of the study was to assess the role of proinflammatory cytokines, chemokines and growth factors in progression of CKD in patients with DM. Patients and Methods: We screened 155 type 2 DM patients aged 65.00 (55.00-71.00) years. Control group included 21 healthy people with the same age. Renal function was assessed based on the levels of serum creatinine, cystatin C, estimated glomerular filtration rate (eGFR), which was calculated according to the CKD-EPI (chronic kidney disease epidemiology collaboration) equation, and albuminuria, which was assessed as albumin/creatinine ratio (A/C). The analysis of serum and urine biomarkers was carried out by enzyme immunoassay using commercial test systems. Results: Patients with DM had significantly higher levels of proinflammatory cytokines in comparison with the control group. The levels of interleukin-6 (IL-6), high-sensitivity C-reactive protein (hs-CRP), vascular endothelial growth factor A (VEGF-A), fibroblast growth factor-23 (FGF-23), regulated upon activation, normal T cell expressed and presumably secreted (RANTES), MIG, CRP, kidney injury molecule-1 (KIM-1) and homocysteine gradually increased with decreasing GFR. According to the results of univariate linear regression analysis, there were significant relationships between the levels of VEGF-A, FGF-23, RANTES, tumor necrosis factor alpha (TNF-alpha), MIG, CRP, hs-CRP, IL-6 and renal function. By multiple linear regression analysis adjusted for confounding factors, serum creatinine was significantly correlated with FGF-23 (β=0.40, P<0.001) and Il-6 (β=0.29, P<0.001). Conclusion: Our study demonstrated the important role of growth factors and proinflammatory cytokines in the development and progression of CKD in DM. However, despite these data, the pathogenesis of diabetic changes in the kidneys remains not fully understood and, in order to clarify the possibility of pathogenetic influences on the progression of diabetic nephropathy, it is necessary to study various aspects of its development, including genetic factors.
- Open Access
- 30 December 2023
- Published by Scientia Publishing House LTD in Juvenis scientia
- Vol. 9 (6) , 18-29
Algorithm for Diagnosing Cardiovascular Pathology in Diabetes Mellitus
Introduction. The association of diabetes mellitus (DM) and cardiovascular diseases (CVD) is due to common pathophysiological processes that determine the prognosis and progression of both diseases. We studied the factors associated with the risk of developing cardiovascular pathology to create an algorithm for diagnosing it in patients diabetes mellitus. Patients and methods. A total of 449 patients (126 men and 323 women) with type 1 diabetes (133) and type 2 diabetes (316) were examined. The median age was 63 (53; 70) years. Serum cystatin C, C-reactive protein (CRP), homocysteine, interleukin-6 (IL-6), N-terminal natriuretic peptide (NTproBNP) and brain natriuretic peptide (BNP) levels, fibroblast growth factor (FGF-23) levels, tumor necrosis factor (TNF-α), chemokine MIG, endothelial growth factor (VEGF-A), chemokine RANTES were determined in all patients. Instrumental research methods included echocardiographic examination and ultrasound of the lower extremity and brachiocephalic arteries. Logistic regression and ROC analysis were used to assess the prognostic value of markers. Results. Cystatin C levels ≥0.96 mg/l were associated with increased natriuretic peptides in patients with diabetes and early stages of CKD (with GFR>60), IL-6 levels ≥2.13 mg/ml and FGF-23 ≥0.9 pmol/ l — with the risk of increasing natriuretic peptides, and IL-6 ≥0.9 pmol/l — with the risk of increase in left ventricular mass index. Based on the obtained results, we developed an algorithm for diagnosis of cardiovascular pathology in patients with diabetes mellitus. Conclusions. In the present study, we identified markers associated with the risk of adverse cardiovascular events in patients with diabetes and their diagnostic value.
- 30 December 2023
- Published by Scientia Publishing House LTD in Juvenis scientia
- Vol. 9 (6) , 18-29
Open AccessAlgorithm for Diagnosing Cardiovascular Pathology in Diabetes Mellitus
Introduction. The association of diabetes mellitus (DM) and cardiovascular diseases (CVD) is due to common pathophysiological processes that determine the prognosis and progression of both diseases. We studied the factors associated with the risk of developing cardiovascular pathology to create an algorithm for diagnosing it in patients diabetes mellitus. Patients and methods. A total of 449 patients (126 men and 323 women) with type 1 diabetes (133) and type 2 diabetes (316) were examined. The median age was 63 (53; 70) years. Serum cystatin C, C-reactive protein (CRP), homocysteine, interleukin-6 (IL-6), N-terminal natriuretic peptide (NTproBNP) and brain natriuretic peptide (BNP) levels, fibroblast growth factor (FGF-23) levels, tumor necrosis factor (TNF-α), chemokine MIG, endothelial growth factor (VEGF-A), chemokine RANTES were determined in all patients. Instrumental research methods included echocardiographic examination and ultrasound of the lower extremity and brachiocephalic arteries. Logistic regression and ROC analysis were used to assess the prognostic value of markers. Results. Cystatin C levels ≥0.96 mg/l were associated with increased natriuretic peptides in patients with diabetes and early stages of CKD (with GFR>60), IL-6 levels ≥2.13 mg/ml and FGF-23 ≥0.9 pmol/ l — with the risk of increasing natriuretic peptides, and IL-6 ≥0.9 pmol/l — with the risk of increase in left ventricular mass index. Based on the obtained results, we developed an algorithm for diagnosis of cardiovascular pathology in patients with diabetes mellitus. Conclusions. In the present study, we identified markers associated with the risk of adverse cardiovascular events in patients with diabetes and their diagnostic value.
- Open Access
- 3 January 2023
- Published by Gomel State Medical University in Health and Ecology Issues
- Vol. 19 (4) , 48-55
Clinical significance of the T(-344)C polymorphism of the aldosterone synthase gene (CYP11B2) in the prognosis of cardiorenal syndrome in diabetes mellitus
Objective. To evaluate the role of the T(-344)C polymorphism of CYP11B2 gene in the development of cardiorenal syndrome (CRS) in diabetes mellitus (DM).Materials and methods. 270 patients with type 1 and type 2 diabetes aged over 25 years were examined. All patients underwent molecular genetic analysis using deoxyribonucleic acid isolated from whole venous blood.Results. The TT genotype was associated with the risk of developing CRS manifestations such as left ventricular hypertrophy (odds ratio (OR) 2.64; 95% CI (0.93–4.19), chronic heart failure (OR 4.26; 95% CI (2.26 - 8.06), subclinical atherosclerosis (OR 4.04; 95% CI (1.89 - 8.58), chronic kidney disease (CKD) (OR 10.77; 95% CI (3.56 - 32.61), and the CT genotype (OR 3.28; 95% CI (1.02 – 10.59) with CKD risk..Conclusion. There are pathogenetic associations between renin-angiotensin-aldosterone system, cardiovascular complications and a decrease of renal function. Further research is needed for a deep understanding of the complex pathogenetic mechanisms of the development and progression of cardiovascular and renal pathology.
- 3 January 2023
- Published by Gomel State Medical University in Health and Ecology Issues
- Vol. 19 (4) , 48-55
Open AccessClinical significance of the T(-344)C polymorphism of the aldosterone synthase gene (CYP11B2) in the prognosis of cardiorenal syndrome in diabetes mellitus
Objective. To evaluate the role of the T(-344)C polymorphism of CYP11B2 gene in the development of cardiorenal syndrome (CRS) in diabetes mellitus (DM).Materials and methods. 270 patients with type 1 and type 2 diabetes aged over 25 years were examined. All patients underwent molecular genetic analysis using deoxyribonucleic acid isolated from whole venous blood.Results. The TT genotype was associated with the risk of developing CRS manifestations such as left ventricular hypertrophy (odds ratio (OR) 2.64; 95% CI (0.93–4.19), chronic heart failure (OR 4.26; 95% CI (2.26 - 8.06), subclinical atherosclerosis (OR 4.04; 95% CI (1.89 - 8.58), chronic kidney disease (CKD) (OR 10.77; 95% CI (3.56 - 32.61), and the CT genotype (OR 3.28; 95% CI (1.02 – 10.59) with CKD risk..Conclusion. There are pathogenetic associations between renin-angiotensin-aldosterone system, cardiovascular complications and a decrease of renal function. Further research is needed for a deep understanding of the complex pathogenetic mechanisms of the development and progression of cardiovascular and renal pathology.
- Open Access
- 9 August 2022
- Published by Endocrinology Research Centre in Osteoporosis and Bone Diseases
- Vol. 25 (1) , 29-38
Bone pathology in chronic kidney disease
The article presents current data on mineral and bone disorders in patients with various stages of chronic kidney disease. The key points of bone lesions pathology are reflected, which include impaired secretion of parathyroid hormone and phosphorus-calcium metabolism, specific osteopathy and extraskeletal calcification, the relationship between bone pathology and cardiovascular complications is indicated. The role of diagnostic tools (FRAX questionnaire, bone densitometry, biochemical parameters and new biological markers) is discussed, approaches to the interpretation of research results are defined. Both general population and specific risk factors for bone strength decrease and occurrence of osteoporotic fractures pathology in chronic kidney disease are described.
- 9 August 2022
- Published by Endocrinology Research Centre in Osteoporosis and Bone Diseases
- Vol. 25 (1) , 29-38
Open AccessBone pathology in chronic kidney disease
The article presents current data on mineral and bone disorders in patients with various stages of chronic kidney disease. The key points of bone lesions pathology are reflected, which include impaired secretion of parathyroid hormone and phosphorus-calcium metabolism, specific osteopathy and extraskeletal calcification, the relationship between bone pathology and cardiovascular complications is indicated. The role of diagnostic tools (FRAX questionnaire, bone densitometry, biochemical parameters and new biological markers) is discussed, approaches to the interpretation of research results are defined. Both general population and specific risk factors for bone strength decrease and occurrence of osteoporotic fractures pathology in chronic kidney disease are described.
- Top Cited PapersOpen Access
Clinical Practice in the Prevention, Diagnosis and Treatment of Vitamin D Deficiency: A Central and Eastern European Expert Consensus Statement
Vitamin D deficiency has a high worldwide prevalence, but actions to improve this public health problem are challenged by the heterogeneity of nutritional and clinical vitamin D guidelines, with respect to the diagnosis and treatment of vitamin D deficiency. We aimed to address this issue by providing respective recommendations for adults, developed by a European expert panel, using the Delphi method to reach consensus. Increasing the awareness of vitamin D deficiency and efforts to harmonize vitamin D guidelines should be pursued. We argue against a general screening for vitamin D deficiency but suggest 25-hydroxyvitamin D (25(OH)D) testing in certain risk groups. We recommend a vitamin D supplementation dose of 800 to 2000 international units (IU) per day for adults who want to ensure a sufficient vitamin D status. These doses are also recommended for the treatment of vitamin D deficiency, but higher vitamin D doses (e.g., 6000 IU per day) may be used for the first 4 to 12 weeks of treatment if a rapid correction of vitamin D deficiency is clinically indicated before continuing, with a maintenance dose of 800 to 2000 IU per day. Treatment success may be evaluated after at least 6 to 12 weeks in certain risk groups (e.g., patients with malabsorption syndromes) by measurement of serum 25(OH)D, with the aim to target concentrations of 30 to 50 ng/mL (75 to 125 nmol/L).
Top Cited PapersOpen AccessClinical Practice in the Prevention, Diagnosis and Treatment of Vitamin D Deficiency: A Central and Eastern European Expert Consensus Statement
Vitamin D deficiency has a high worldwide prevalence, but actions to improve this public health problem are challenged by the heterogeneity of nutritional and clinical vitamin D guidelines, with respect to the diagnosis and treatment of vitamin D deficiency. We aimed to address this issue by providing respective recommendations for adults, developed by a European expert panel, using the Delphi method to reach consensus. Increasing the awareness of vitamin D deficiency and efforts to harmonize vitamin D guidelines should be pursued. We argue against a general screening for vitamin D deficiency but suggest 25-hydroxyvitamin D (25(OH)D) testing in certain risk groups. We recommend a vitamin D supplementation dose of 800 to 2000 international units (IU) per day for adults who want to ensure a sufficient vitamin D status. These doses are also recommended for the treatment of vitamin D deficiency, but higher vitamin D doses (e.g., 6000 IU per day) may be used for the first 4 to 12 weeks of treatment if a rapid correction of vitamin D deficiency is clinically indicated before continuing, with a maintenance dose of 800 to 2000 IU per day. Treatment success may be evaluated after at least 6 to 12 weeks in certain risk groups (e.g., patients with malabsorption syndromes) by measurement of serum 25(OH)D, with the aim to target concentrations of 30 to 50 ng/mL (75 to 125 nmol/L).
- 1 February 2022
- Published by Publishing House Belorusskaya Nauka in Science and Innovations
- Vol. 2 (228)
New biomedical cell products for immunotherapy of human diseases
Cellular therapy develops rapidly throughout the world. The list of diseases of various etiologies that are treated with biomedical cellular products is constantly growing. The Center for Immunology and Allergology was opened in the The Institute of Biophysics and Cell Engineering of National Academy of Science of Belarus in 2021. Since that the developing of new biomedical cell products for the correction of immunopathological conditions was started in collaboration with the Belarusian State Medical University. The technologies for producing of biomedical cellular products based on cytokine-induced killer cells for the treatment of oncological diseases of the urogenital area, tolerogenic dendritic cells for the treatment of type 1 diabetes, and regulatory T lymphocytes for the treatment of sclerosis were developed.
- 1 February 2022
- Published by Publishing House Belorusskaya Nauka in Science and Innovations
- Vol. 2 (228)
New biomedical cell products for immunotherapy of human diseases
Cellular therapy develops rapidly throughout the world. The list of diseases of various etiologies that are treated with biomedical cellular products is constantly growing. The Center for Immunology and Allergology was opened in the The Institute of Biophysics and Cell Engineering of National Academy of Science of Belarus in 2021. Since that the developing of new biomedical cell products for the correction of immunopathological conditions was started in collaboration with the Belarusian State Medical University. The technologies for producing of biomedical cellular products based on cytokine-induced killer cells for the treatment of oncological diseases of the urogenital area, tolerogenic dendritic cells for the treatment of type 1 diabetes, and regulatory T lymphocytes for the treatment of sclerosis were developed.
- 1 January 2022
- Published by Geotar-Media Publishing Group in Problems of Nutrition
- Vol. 91 (3) , 53-63
On integration of the iodine deficiency elimination and salt reduction programs
К вопросу интеграции программ ликвидации йоддефицита и снижения потребления соли
- 1 January 2022
- Published by Geotar-Media Publishing Group in Problems of Nutrition
- Vol. 91 (3) , 53-63
On integration of the iodine deficiency elimination and salt reduction programs
К вопросу интеграции программ ликвидации йоддефицита и снижения потребления соли
- Open Access
- 27 December 2021
- Published by Publishing House Zaslavsky in INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine)
- Vol. 17 (8) , 596-603
Leptin and adiponectin in patients with chronic kidney disease and secondary hyperparathyroidism
Background. The results of studies evaluating the levels of adiponectin, leptin and their ratios in chronic kidney disease (CKD) are conflicting. It is assumed that hyperleptinemia and changes in adiponectin clearance are consequences of a decrease in the glomerular filtration rate, they exacerbate renal impairment and may affect the prognosis of survival due to cardiovascular events. It is known that secondary hyperaparathyroidism is the most frequent complication of CKD, which not only affects calcium-phosphorus metabolism and bone tissue, but also contributes to the development of pathological processes involving other hormonal and metabolic markers. Of greatest interest is the assessment of adipocytokine levels in the development of secondary hyperparathyroidism against the background of CKD as an independent factor of increasing cardiovascular risks. The purpose of the study was to assess adipocytokine levels (adiponectin, leptin) and their ratios in patients with different stages of chronic kidney disease and their relationship with manifestations of secondary hyperparathyroidism. Materials and methods. This cross-sectional study enrolled 160 people with CKD and 40 healthy individuals as a comparison group. Results. Leptin level reduction and an increase in the proportion of patients with hypoleptinemia with a decrease in the glomerular filtration rate were found, which may be an important factor determining nutritional status. Correlations were revealed between leptin level, body mass index (ρ = 0.411) and patients’ age (ρ = 0.189), as well as between leptin/adiponectin and adiponectin/leptin ratios (ρ = 0.395 and ρ = –0.395) and body mass index in patients with CKD persisting in subgroups by stage of renal failure. A relationship was found with sex for leptin and a decrease in its levels below normal values in both men and women. Conclusions. The proportion of patients with hyperadiponectinemia was significantly higher among those with end-stage CKD compared to patients with stages 1–2. There was no statistically significant relationship between adipocytokine and parathyroid hormone levels and the presence of secondary hyperparathyroidism in patients examined.
- 27 December 2021
- Published by Publishing House Zaslavsky in INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine)
- Vol. 17 (8) , 596-603
Open AccessLeptin and adiponectin in patients with chronic kidney disease and secondary hyperparathyroidism
Background. The results of studies evaluating the levels of adiponectin, leptin and their ratios in chronic kidney disease (CKD) are conflicting. It is assumed that hyperleptinemia and changes in adiponectin clearance are consequences of a decrease in the glomerular filtration rate, they exacerbate renal impairment and may affect the prognosis of survival due to cardiovascular events. It is known that secondary hyperaparathyroidism is the most frequent complication of CKD, which not only affects calcium-phosphorus metabolism and bone tissue, but also contributes to the development of pathological processes involving other hormonal and metabolic markers. Of greatest interest is the assessment of adipocytokine levels in the development of secondary hyperparathyroidism against the background of CKD as an independent factor of increasing cardiovascular risks. The purpose of the study was to assess adipocytokine levels (adiponectin, leptin) and their ratios in patients with different stages of chronic kidney disease and their relationship with manifestations of secondary hyperparathyroidism. Materials and methods. This cross-sectional study enrolled 160 people with CKD and 40 healthy individuals as a comparison group. Results. Leptin level reduction and an increase in the proportion of patients with hypoleptinemia with a decrease in the glomerular filtration rate were found, which may be an important factor determining nutritional status. Correlations were revealed between leptin level, body mass index (ρ = 0.411) and patients’ age (ρ = 0.189), as well as between leptin/adiponectin and adiponectin/leptin ratios (ρ = 0.395 and ρ = –0.395) and body mass index in patients with CKD persisting in subgroups by stage of renal failure. A relationship was found with sex for leptin and a decrease in its levels below normal values in both men and women. Conclusions. The proportion of patients with hyperadiponectinemia was significantly higher among those with end-stage CKD compared to patients with stages 1–2. There was no statistically significant relationship between adipocytokine and parathyroid hormone levels and the presence of secondary hyperparathyroidism in patients examined.